Giora Sharf's guest appearances

Giora Sharf

17th European Haematology Association (EHA) Congress

John Porter

Michael Keating

Jan Geissler

Willem Fibbe

Charles Mullighan

Jing Chen

Mark Frattini

OwlTail

Giora Sharf, Director of the Israeli CML Patients Support Group, talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about what patients have contributed to the study of chronic myeloid leukaemia. A large issue in the patient community is that of adherence, which the CML Patients Support Group aims to address through a new, large scale survey. In previous studies, the group found that 25 to 30% of patients do not take the drugs given to them, and this can have extremely detrimental effects on a patient’s outcome. If a patient takes less than 90% of dosage, they only have ¼ of chance to achieve complete response.  Reasons cited for a lack of adherence range from too many negative side effects to forgetfulness.

Giora Sharf, Director of the Israeli CML Patients Support Group, talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about what patients have contributed to the study of chronic myeloid leukaemia.<br> <br>A large issue in the patient community is that of adherence, which the CML Patients Support Group aims to address through a new, large scale survey. In previous studies, the group found that 25 to 30% of patients do not take the drugs given to them, and this can have extremely detrimental effects on a patient’s outcome.<br> <br>If a patient takes less than 90% of dosage, they only have ¼ of chance to achieve complete response.  Reasons cited for a lack of adherence range from too many negative side effects to forgetfulness.

Addressing the problem of adherence to treatment: Giora Sharf – Israeli CML Patients Support Group